Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2025
0mins
Source: Globenewswire
Clinical Trial Progress: Gain Therapeutics has successfully enrolled 16 participants in its Phase 1b clinical trial for GT-02287, aimed at treating Parkinson's disease, ahead of the target goal of 15 by Q3 2025. The study will now provide biomarker analysis results earlier than expected, in Q4 2025.
Future Plans and Extensions: The company plans to extend patient screening until July 31, 2025, and is seeking to prolong the dosing period beyond the current 90 days to better inform future trial designs, with updates anticipated before the end of Q3 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
